Clinical Research Directory
Browse clinical research sites, groups, and studies.
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Sponsor: Teclison Ltd.
Summary
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Official title: An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2021-05-20
Completion Date
2025-12-31
Last Updated
2024-11-22
Healthy Volunteers
No
Conditions
Interventions
TATE and pembrolizumab
All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
TAS-102 pill
The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
Regorafenib Pill
As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
Locations (3)
University of California, Irvine Medical Center
Orange, California, United States
China Medical University Hsinchu Hospital
Hsinchu, Taiwan
Chung Shan Medical University Hospital
Taichung, Taiwan